Tandem Historical Cash Flow
| TNDM Stock | USD 32.66 1.66 5.35% |
Analysis of Tandem Diabetes cash flow over time is an excellent tool to project Tandem Diabetes Care future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 19 M or Other Non Cash Items of 126.4 M as it is a great indicator of Tandem Diabetes ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Tandem Diabetes Care latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Tandem Diabetes Care is a good buy for the upcoming year.
Tandem |
About Tandem Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Tandem balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Tandem's non-liquid assets can be easily converted into cash.
Tandem Diabetes Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Tandem Diabetes Care to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Tandem Diabetes operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Tandem Diabetes' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Tandem Diabetes Care current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. At this time, Tandem Diabetes' Change To Account Receivables is very stable compared to the past year. As of the 26th of February 2025, Sale Purchase Of Stock is likely to grow to about 25.1 M, though Free Cash Flow is likely to grow to (91.1 M).
Tandem Diabetes cash flow statement Correlations
Click cells to compare fundamentals
Tandem Diabetes Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Tandem Diabetes cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 43.4M | (23.4M) | 101.3M | (113.6M) | (102.3M) | (97.2M) | |
| Stock Based Compensation | 58.4M | 60.8M | 84.9M | 88.1M | 101.3M | 106.4M | |
| Free Cash Flow | (7.6M) | 87.8M | 7.5M | (83.4M) | (95.9M) | (91.1M) | |
| Change In Working Capital | (36.6M) | 14.4M | (4.6M) | (17.7M) | (15.9M) | (15.1M) | |
| Begin Period Cash Flow | 51.2M | 94.6M | 71.2M | 172.5M | 198.4M | 208.3M | |
| Total Cashflows From Investing Activities | (57.0M) | (296.1M) | (186.9M) | 33.2M | 29.9M | 31.3M | |
| Other Cashflows From Financing Activities | 35.7M | 51.9M | 16.9M | 4.1M | 3.7M | 3.5M | |
| Depreciation | 10.5M | 13.8M | 14.3M | 15.7M | 18.1M | 19.0M | |
| Other Non Cash Items | 28.9M | 2.3M | 50.5M | 104.7M | 120.4M | 126.4M | |
| Capital Expenditures | 32.3M | 23.5M | 43.0M | 51.6M | 59.3M | 62.3M | |
| Total Cash From Operating Activities | 24.7M | 111.4M | 50.5M | (31.8M) | (36.6M) | (34.8M) | |
| Change To Account Receivables | (38.8M) | (31.0M) | (7.8M) | 4.3M | 3.8M | 4.0M | |
| Net Income | (34.4M) | 15.6M | (94.6M) | (222.6M) | (200.3M) | (190.3M) | |
| Total Cash From Financing Activities | 314.4M | 51.9M | 16.9M | 4.1M | 4.7M | 4.5M | |
| End Period Cash Flow | 94.6M | 71.2M | 172.5M | 58.9M | 67.7M | 65.4M | |
| Change To Liabilities | 28.9M | 12.9M | 33.7M | 13.1M | 15.1M | 11.8M | |
| Change To Inventory | (15.4M) | (5.0M) | (42.5M) | (46.1M) | (41.4M) | (39.4M) | |
| Sale Purchase Of Stock | 24.2M | 69.8M | 51.9M | 17.6M | 20.2M | 25.1M | |
| Investments | (263.8M) | (163.4M) | 33.2M | (85.7M) | (77.2M) | (81.0M) | |
| Change Receivables | (13.7M) | (38.8M) | (31.0M) | (7.8M) | (7.0M) | (7.4M) | |
| Cash And Cash Equivalents Changes | 9.2M | 43.1M | (23.6M) | 100.5M | 115.6M | 121.4M | |
| Cash Flows Other Operating | 3.4M | 4.7M | 16.6M | 40.1M | 46.1M | 48.4M | |
| Change To Operating Activities | 18.8M | 9.5M | 29.4M | 12.8M | 14.7M | 11.5M | |
| Other Cashflows From Investing Activities | (4.9M) | (9.3M) | (8.9M) | (24.8M) | (22.3M) | (23.4M) | |
| Change To Netincome | 73.5M | 76.4M | 65.5M | 121.7M | 140.0M | 147.0M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (1.94) | Revenue Per Share | Quarterly Revenue Growth 0.314 | Return On Assets |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.